

\*\*\*\*New release July 2010\*\*\*\*

## MarketVIEW: Cytomegalovirus (CMV) vaccines (CAT: VAMV014)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	MarketVIEW: Cytomegalovirus vaccines – Global market forecast
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	<i>Novel/adolescent vaccines</i>
<b>Product (if applicable)</b>	:	<b>CAT No:</b> VAMV014, published July 2010

## Background

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

Vaccine manufacturers are currently pursuing both therapeutic (TX) and prophylactic (PX) CMV vaccine approaches. The most advanced program is Sanofi Pasteur's gB vaccine (+ MF59 adjuvant) where protective efficacy has been shown in post-partum women (Phase II). Other notable approaches are Vical's VCL-CB01 DNA-based approach in HSCT seropositive recipient (Phase II).

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX +PX approaches) across major Western and emerging markets to 2030. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. **LO/BASE/HI** forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Cytomegalovirus (CMV) epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of adolescent female vaccines has also been utilised.

### **PRODUCT CONTENTS:**

**Published July 2010 (CAT No: VAM014)**

\*\*\*\*This product is composed of a model and summary presentation

#### **Contents – Summary presentation (MS PowerPoint based)**

- Author's note
- Executive summary
- Total global predicted demand (doses 000s): all scenarios
- Total global available market (\$ 000s): all scenarios
- Total global available market, high case (\$ 000s)
- Predicted revenue per competitor to 2030
- CMV vaccines: value per indication analysis (\$m)
- Key model assumptions
- The role of a CMV vaccine
- Markets included in the model
- Population segments included in model
- Commercial model assumptions
- Estimated filing dates per indication
- Vaccine target product profile
- Commercial model assumptions per country
- Methodology – transplant population
- Methodology – child bearing female population
- Methodology – adolescent vaccination
- CMV vaccine pipeline
- Bibliography
- About VacZine Analytics
- Disclaimer

**PAGES: 30 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

#### **Contents – Vaccine demand model (MS Excel-based)**

- Title sheet
- Scenario definitions
- Total CHARTS
- CHARTS – LO/BASE/HI value
- CHARTS – LO/BASE/HI volume
- VALUE SUMMARY – total market
- VOLUME SUMMARY – total market
- US lo/base/hi

## Contents – Vaccine demand model (MS Excel-based) - continued

Canada lo/base/hi  
UK lo/base/hi  
France lo/base/hi  
Germany lo/base/hi  
Italy lo/base/hi  
Spain lo/base/hi  
EU other lo/base/hi  
Japan lo/base/hi  
Australia lo/base/hi  
Brazil lo/base/hi  
India lo/base/hi  
Russia lo/base/hi  
China lo/base/hi  
Mexico lo/base/hi  
Per country vaccine target populations  
Source material  
Assumptions  
CMV serostatus  
CMV by age US  
Solid Organ transplants  
Haematopoietic Transplants  
Population database  
Disclaimer  
BACK PAGE

**WORKSHEETS: ~65**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- USD \$7995.00/ GBP £5499.00 (Region license)\*

\*A region is North America, Europe or ROW  
For orders in the UK, VAT at 17.5% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)  
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728  
**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

1. Weikert BC et al. Viral infection after renal transplantation: surveillance and management. *Clin J Am Soc Nephrol*. 2008 Mar;3 Suppl 2:S76-86
2. Ljungman P et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. *Transplantation* 1998;66:1330–1334.
3. Rossini F et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. *Transpl Infect Dis*. 2005 Sep-Dec;7(3-4):122-5.
4. Organ Procurement and Transplantation Network. Available at: <http://optn.transplant.hrsa.gov/>. Accessed May 2010.
5. Global Observatory of Donation and Transplantation. Available at: <http://www.transplant-observatory.org/>. Accessed May 2010.
6. Center for International Blood and Marrow Transplant Research (CIBMTR) newsletters; published 2002-2009. Available at: <http://www.cibmtr.org/>. Accessed May 2010.
7. Asia Pacific Blood and Marrow Transplantation Group (APBMT). Available at: <http://www.apbmt.org/>. Accessed May 2010.
8. Gratwohl A et al. Hematopoietic stem cell transplantation: a global perspective. *JAMA*. 2010 Apr 28;303(16):1617-24.
9. Ljungman P et al. Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors. *Haematologica*. 2007 Aug;92(8):1139-42.
10. Beck JC et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. *Biol Blood Marrow Transplant*. 2010 Feb;16(2):215-22.
11. Fowler KB et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. *N Engl J Med* 326:663-667, 1992
12. Adler SP et al. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. *Semin Perinatol*. 2007 Feb;31(1):10-8.
13. Arvin AM et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. *Clin Infect Dis*. 2004 Jul 15;39(2):233-9.
14. Pass RF et al. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. *J Clin Virol*. 2006 Feb;35(2):216-20.
15. Colugnati FA et al. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. *BMC Infect Dis*. 2007 Jul 2;7:71.
16. Chandra A et al. Fertility, family planning, and reproductive health of U.S. women: Data from the 2002 National Survey of Family Growth. National Center for Health Statistics. *Vital Health Stat* 23(25). 2005
17. Biermann, J. National Healthy Start Conference. Washington, DC March 27, 2006. Available at: [www.healthystartassoc.org](http://www.healthystartassoc.org). Accessed: May 2010.
18. Johnson K et al. Recommendations to Improve Preconception Health and Health Care — United States: a report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. *MMWR Recomm Rep*. 2006;55(RR-6):1-23.
19. Munoz FM et al. Safety of influenza vaccination during pregnancy. *Am J Obstet Gynecol* 2005;192:1098–106
20. Cook GA et al. Uptake of rubella vaccine among susceptible adults. *Community Med*. 1987 Aug;9(3):254-9.
21. Staras SA et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. *Clin Infect Dis*. 2006 Nov 1;43(9):1143-51.
22. Pass RF et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med*. 2009 Mar 19;360(12):1191-9
23. TransVax CMV Therapeutic DNA Vaccine. World Vaccine Congress. April 22, 2010.

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009